Table 3 Correlations between TRYCATs and psychopathological dimensions.

	Motivation and pleasure dimension (BNSS)	Cognitive symptom dimension (BNA)
Tryptophan (nM)	SZ: r(p) = − 0.043, p = 0.781 MDD: r(p) = 0.070, p = 0.657	SZ: r(p) = − 0.022, p = 0.887 MDD: r(p) = 0.080, p = 0.616
Kynurenine (nM)	SZ: r(p) = − 0.092, p = 0.49 MDD: r(p) = − 0.217, p = 0.162	SZ: r(p) = − 0.209, p = 0.179 MDD: r(p) = 0.052, p = 0.741
Tryptophan/kynurenine (log¹)	SZ: r(p) = − 0.013, p = 0.933 MDD: r(p) = − 0.199, p = 0.200	SZ: r(p) = − 0.146, p = 0.349 MDD: r(p) = − 0.016, p = 0.919
Kynurenic acid (nM) (log¹)	SZ: r(p) = − 0.099, p = 0.519 MDD: r(s) = − 0.211, p = 0.174	SZ: r(p) = − 0.186, p = 0.233 MDD: r(s) = − 0.059, p = 0.711
3-Hydroxy kynurenine (nM)	SZ: r(p) = − 0.025, p = 0.870 MDD: r(p) = − 0.202, p = 0.195	SZ: r(p) = − 0.089, p = 0.571 MDD: r(p) = − 0.126, p = 0.425
Kynurenine/3-hydroxy kynurenine	SZ: r(p) = 0.034, p = 0.823 MDD: r(p) = 0.057, p = 0.715	SZ: r(p) = − 0.061, p = 0.698 MDD: r(p) = 0.159, p = 0.316
Kynurenic acid/3-hydroxy kynurenine (log^1,2)	SZ: r(p) = − 0.067, p = 0.663 MDD: r(p) = − 0.155, p = 0.321	SZ: r(p) = − 0.131, p = 0.401 MDD: r(p) = 0.019, p = 0.905
Quinolinic acid (nM) (log^1,2)	SZ: r(p) = 0.104, p = 0.495 MDD: r(p) = − 0.177, p = 0.256	SZ: r(p) = − 0.324, p = 0.034 MDD: r(p) = − 0.056, p = 0.723
Kynurenine acid/quinolinic acid (log^1,2)	SZ: r(p) = − 0.167, p = 0.273 MDD: r(p) = − 0.116, p = 0.459	SZ: r(p) = 0.160, p = 0.306 MDD: r(p) = 0.012, p = 0.941

Statistics: ¹log₁₀-transformation achieved normal distribution in patients with SZ, ²log₁₀-transformation achieved normal distribution in patients with MDD. BNA Brief Neurocognitive Assessment, BNSS Brief Negative Symptom Scale, HC Healthy controls, MDD Major depressive disorder, SZ Schizophrenia. Data is presented as mean ± standard deviation. The level of significance was set at p < 0.05 (significant p-values are indicated in bold).

Search